相关实验视频

Updated: May 7, 2026

A Novel Method: Super-selective Adrenal Venous Sampling

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

抑制ACE以区分低蛋白高血压与初级阿尔多斯特主义

Cheng-Hsuan Tsai^1,2,3, Jenifer M Brown^1,4, Stefanie Parisien-La Salle^1,5

¹Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (C.-H.T., J.M.B., S.P.-L.S., A.J.N., A.V.).

Hypertension (Dallas, Tex. : 1979)

|March 31, 2025

概括

使用卡普托普里尔挑战测试,区分原发性阿尔多斯特隆症 (PA) 和低蛋白高血压 (LRH) 是复杂的. 针对阿尔多的向治疗对疑似PA的患者提供了显著的益处,无论诊断解释如何.

科学领域:

内分泌学在内分泌学.
高血压研究高血压研究
临床诊断临床诊断临床诊断

背景情况:

原发性阿尔多斯 (PA) 是低蛋白高血压 (LRH) 的关键原因,由过度的阿尔多斯生产驱动.
研究LRH和PA之间的差异对于有效的患者管理至关重要.
抑制 ангиотензин转化酶提供了一个生理学工具来探索这一区别.

研究的目的:

评估卡普托普里尔挑战试验 (CCT) 在区分PA与LRH的诊断实用性.
评估不同CCT解释标准对PA分类的影响.
在怀疑PA的患者中,分析阿尔多素向治疗后的治疗结果.

主要方法:

一个回顾性队列研究,对756名LRH患者进行了PA评估的CCT.
用四个不同的CCT标准对PA与LRH进行评估,这些标准基于测试后的氨酸和氨酸水平.
使用已确立的初级阿尔多斯特罗尼斯手术结果和医疗结果标准对纵向结果的评估.

主要成果:

在CCT后观察到连续的阿尔多斯特生产频谱,模糊了LRH和PA之间的界限.
根据CCT解释标准,PA的分类差异很大 (57.8%-66.3%以双重标准对比82.5%-95.1%以单一标准).
高治疗响应率 (86.5%-91.7%) 是通过阿尔多的向疗法实现的,不论是CCT解释方法.

结论:

在LRH和PA之间的区别往往是模糊的,即使在captopril挑战测试.
虽然特定的CCT标准可以最大限度地捕捉PA病例,但阿尔多激素向治疗在患者群体中产生一致的益处.
在LRH患者中,经验性阿尔多激素导向治疗可能是广泛的诊断工作的实用替代方案,用于疑似PA患者.

关键词:

阿尔多斯氨酸是一种阿尔多斯氨酸.卡普托普里尔 (captopril) 是一个人类人类人类人类人类人类.这种高血压,高血压.雷宁 (renin) 是一种蛋白质.

更多相关视频

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

相关概念视频

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...

Antihypertensive Drugs: Potassium-Sparing Diuretics

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...